Profund Advisors LLC Sells 23,180 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Profund Advisors LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 27.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,616 shares of the biopharmaceutical company’s stock after selling 23,180 shares during the period. Profund Advisors LLC’s holdings in TG Therapeutics were worth $1,114,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TGTX. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth about $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics in the 2nd quarter worth approximately $35,000. DekaBank Deutsche Girozentrale bought a new stake in shares of TG Therapeutics in the 1st quarter worth approximately $58,000. Lazard Asset Management LLC purchased a new position in shares of TG Therapeutics during the first quarter valued at approximately $91,000. Finally, nVerses Capital LLC raised its holdings in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 5.7 %

NASDAQ:TGTX opened at $23.25 on Tuesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The firm’s 50-day moving average price is $22.12 and its 200-day moving average price is $18.38. The company has a market capitalization of $3.59 billion, a PE ratio of 101.09 and a beta of 2.21. TG Therapeutics, Inc. has a 1-year low of $6.46 and a 1-year high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same quarter last year, the firm earned ($0.34) earnings per share. The business’s revenue for the quarter was up 357.0% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TGTX shares. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. B. Riley lifted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.